Anzeige
Mehr »
Login
Mittwoch, 29.01.2025 Börsentäglich über 12.000 News von 684 internationalen Medien
Absoluter Geheimtipp: Vergessen Sie Gold, Silber und Uran!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
550 Leser
Artikel bewerten:
(2)

Eldorado Gold Corporation: Eldorado Gold Announces Appointment of Paul Ferneyhough as Executive Vice President and Chief Financial Officer

Finanznachrichten News

VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Eldorado Gold Corporation ("Eldorado" or the "Company") today announces the appointment of Paul Ferneyhough as Executive Vice President and Chief Financial Officer of the Company to be effective today, January 2, 2024. Mr. Ferneyhough will be succeeding Philip Yee, who will be retiring as of the same date.

Paul Ferneyhough joined Eldorado Gold in May 2021 to oversee the development and execution of the Company's strategic growth strategy. Most recently, Paul was Executive Vice President, Chief Strategy & Commercial Officer of Eldorado, with accountabilities including Country Management (Canada, Greece and Turkiye), Investor Relations, Sales & Marketing, Business Improvement, and Supply Chain & Procurement. Paul joined the Company as Senior Vice President, Chief Growth and Integration Officer. In that role, Paul was Eldorado's lead negotiator for the Skouries Project Financing Facility that was successfully closed at very competitive rates in early 2023. Prior to joining Eldorado Gold, Paul spent nearly two decades with Repsol SA (and Talisman Energy), most recently as Executive Director leading Repsol's North American upstream oil and gas division. At Repsol, Paul held progressively senior leadership roles in corporate, line and functional areas including finance, investor relations, strategy, commercial, planning and business performance management.

In addition to his 30 years of resource industry experience, Paul is also a Chartered Accountant and a member of the Institute of Chartered Accountants of England and Wales. In his new role as CFO, Paul will retain his current reporting lines except for Investor Relations and Country Management, responsibility for which will be assumed by other members of the Executive team. Paul will also assume responsibility for Human Resources.

"On behalf of Eldorado's board and management, I would like to thank Phil for his dedication and significant contributions to the company over the past five years," said George Burns, President and Chief Executive Officer. "We wish he and his family the very best in his well-deserved retirement."

"Since joining Eldorado, Paul has progressively assumed more responsibility, has been a strong contributor to the overall success of the organization, and has become the natural successor as CFO. I look forward to continuing to work closely with Paul as we continue to focus on unlocking the value across our portfolio, optimizing our cost structure, and transitioning to delivering sustained free cash flow over the next couple of years," added Mr. Burns.

About Eldorado Gold

Eldorado is a gold and base metals producer with mining, development and exploration operations in Turkiye, Canada and Greece. The Company has a highly skilled and dedicated workforce, safe and responsible operations, a portfolio of high-quality assets, and long-term partnerships with local communities. Eldorado's common shares trade on the Toronto Stock Exchange (TSX: ELD) and the New York Stock Exchange (NYSE: EGO).

Contact

Investor Relations

Lynette Gould, VP, Investor Relations
647 271 2827 or 1 888 353 8166
lynette.gould@eldoradogold.com

Media

Chad Pederson, Director, Communications
236 885 6251 or 1 888 353 8166
chad.pederson@eldoradogold.com



© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.